Pfizer Inc.'s plans to market its pneumonia vaccine to older adults has received an icy reception from advisers for the U.S. Centers for Disease Control, who are waiting for more data before recommending that doctors administer the drug.
The CDC said Wednesday, just weeks after the U.S. Food and Drug Administration had OK'd the use of Prevnar 13 in adults 50 and over, that it will review data from a drug trial in Netherlands to be completed next year. Editor's note: This corrects an earlier version of this story, which identified the wrong country.
Pfizer said its marketing campaign will go forward. The delay isn't affecting its financial forecast for this year, Pfizer told Reuters news service.